Mia's Feed
Mental Health & Mindfulness

Race and Ethnicity Often Not Reported in Clinical Trials for Mental Health Medications

Race and Ethnicity Often Not Reported in Clinical Trials for Mental Health Medications

Share this article

2 min read

A recent comprehensive review led by the University of Southampton has highlighted a significant gap in the reporting of race and ethnicity data in clinical trials for mental health and neurodevelopmental treatments. The study, published in JAMA Psychiatry, analyzed over 1,600 randomized controlled trials and found that only approximately 39% of them included information on participants’ racial or ethnic backgrounds. This lack of detailed demographic reporting is particularly concerning for underrepresented groups such as Hispanic, Asian, and Black populations, especially within U.S.-based studies.

The absence of consistent data on race and ethnicity limits our understanding of how different populations respond to mental health medications, impeding the development of tailored and effective treatments. Dr. Alessio Bellato emphasized the importance of recognizing variations among racial and ethnic groups to improve efficacy and tolerability of therapies. The study also revealed that although reporting on race and ethnicity has increased in the U.S. since 1980, progress remains uneven globally, with many regions still lacking comprehensive demographic data.

Most of the trials reviewed—over 375,000 participants—were conducted in Europe and the United States. The researchers stress the need for international guidelines to improve the reporting standards and promote equitable recruitment across diverse populations. Such measures would enhance the generalizability of research findings and ensure treatments are effective for all.

Senior author NIHR Research Professor Samuele Cortese called for global efforts to establish better reporting practices in scientific publications and clinical trials. This initiative aims to reduce biases, improve inclusivity, and better serve diverse patient populations worldwide.

For more details, see the study titled "Reporting and Representation of Race and Ethnicity in Clinical Trials of Pharmacotherapy for Mental Disorders" in JAMA Psychiatry (2025). Source: https://medicalxpress.com/news/2025-05-ethnicity-trials-medications-mental-health.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Exploring Dopamine's Role in Shaping Future-Ready Artificial Intelligence

New research uncovers how dopamine neurons in the brain create detailed maps of future rewards, inspiring advancements in AI that can adapt more flexibly to change and uncertainty.

Talking Therapy Shows Promise in Enhancing Recovery for Stroke Survivors

New research demonstrates that talking therapies significantly improve mental health recovery in stroke survivors, emphasizing early intervention and tailored approaches to maximize benefits.